WO2005095403A3 - Composes macrocycliques inhibiteurs de replication virale - Google Patents

Composes macrocycliques inhibiteurs de replication virale Download PDF

Info

Publication number
WO2005095403A3
WO2005095403A3 PCT/US2005/010494 US2005010494W WO2005095403A3 WO 2005095403 A3 WO2005095403 A3 WO 2005095403A3 US 2005010494 W US2005010494 W US 2005010494W WO 2005095403 A3 WO2005095403 A3 WO 2005095403A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
inhibitors
viral replication
macrocyclic compounds
subject compound
Prior art date
Application number
PCT/US2005/010494
Other languages
English (en)
Other versions
WO2005095403B1 (fr
WO2005095403A2 (fr
Inventor
Lawrence M Blatt
Steven M Wenglowsky
Steven W Andrews
Kevin R Condroski
Yutong Jiang
April L Kennedy
George A Doherty
John A Josey
Peter J Stengel
Benjamin T Woodard
Machender R Madduru
Original Assignee
Intermune Inc
Lawrence M Blatt
Steven M Wenglowsky
Steven W Andrews
Kevin R Condroski
Yutong Jiang
April L Kennedy
George A Doherty
John A Josey
Peter J Stengel
Benjamin T Woodard
Machender R Madduru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ549697A priority Critical patent/NZ549697A/en
Priority to EA200601467A priority patent/EA012389B1/ru
Priority to BRPI0509467-4A priority patent/BRPI0509467A/pt
Priority to UAA200611368A priority patent/UA91677C2/ru
Application filed by Intermune Inc, Lawrence M Blatt, Steven M Wenglowsky, Steven W Andrews, Kevin R Condroski, Yutong Jiang, April L Kennedy, George A Doherty, John A Josey, Peter J Stengel, Benjamin T Woodard, Machender R Madduru filed Critical Intermune Inc
Priority to EP05757750A priority patent/EP1749007A2/fr
Priority to CA2560897A priority patent/CA2560897C/fr
Priority to AU2005228894A priority patent/AU2005228894B9/en
Priority to JP2007506466A priority patent/JP4950026B2/ja
Publication of WO2005095403A2 publication Critical patent/WO2005095403A2/fr
Publication of WO2005095403A3 publication Critical patent/WO2005095403A3/fr
Publication of WO2005095403B1 publication Critical patent/WO2005095403B1/fr
Priority to IL177917A priority patent/IL177917A0/en
Priority to TNP2006000308A priority patent/TNSN06308A1/en
Priority to NO20064933A priority patent/NO20064933L/no
Priority to IS8563A priority patent/IS8563A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des composés représentés par les formules générales (I à XIX), ainsi que des compositions, et notamment des compositions pharmaceutiques à base d'un composé de l'invention. L'invention concerne également un procédé permettant de traiter des infections flavivirales, hépatite C comprise, ainsi que la fibrose hépatique, en administrant à l'individu atteint une quantité suffisante d'un composé ou d'une composition de l'invention.
PCT/US2005/010494 2004-03-30 2005-03-29 Composes macrocycliques inhibiteurs de replication virale WO2005095403A2 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CA2560897A CA2560897C (fr) 2004-03-30 2005-03-29 Composes macrocycliques inhibiteurs de replication virale
BRPI0509467-4A BRPI0509467A (pt) 2004-03-30 2005-03-29 compostos macrocìclicos como inibidores de replicação viral
UAA200611368A UA91677C2 (ru) 2004-03-30 2005-03-29 Макроциклические соединения как ингибиторы вирусной репликации
JP2007506466A JP4950026B2 (ja) 2004-03-30 2005-03-29 ウイルス複製阻害剤としての大環状化合物
EP05757750A EP1749007A2 (fr) 2004-03-30 2005-03-29 Composes macrocycliques inhibiteurs de replication virale
EA200601467A EA012389B1 (ru) 2004-03-30 2005-03-29 Макроциклические соединения в качестве ингибиторов вирусной репликации
AU2005228894A AU2005228894B9 (en) 2004-03-30 2005-03-29 Macrocyclic compounds as inhibitors of viral replication
NZ549697A NZ549697A (en) 2004-03-30 2005-03-29 Macrocyclic compounds as inhibitors of viral replication
IL177917A IL177917A0 (en) 2004-03-30 2006-09-06 Macrocyclic compounds as inhibitors of viral replication
TNP2006000308A TNSN06308A1 (en) 2004-03-30 2006-09-27 Macrocyclic compounds as inhibitors of viral replication
NO20064933A NO20064933L (no) 2004-03-30 2006-10-27 Makrosykliske forbindelser som inhibitorer av viral replikasjon
IS8563A IS8563A (is) 2004-09-22 2006-10-30 Makrósýklísk efnasambönd sem hindra veirueftirmyndun

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US55816104P 2004-03-30 2004-03-30
US60/558,161 2004-03-30
US56241804P 2004-04-14 2004-04-14
US60/562,418 2004-04-14
US61238104P 2004-09-22 2004-09-22
US61246004P 2004-09-22 2004-09-22
US60/612,460 2004-09-22
US60/612,381 2004-09-22

Publications (3)

Publication Number Publication Date
WO2005095403A2 WO2005095403A2 (fr) 2005-10-13
WO2005095403A3 true WO2005095403A3 (fr) 2005-12-01
WO2005095403B1 WO2005095403B1 (fr) 2006-02-02

Family

ID=35005653

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/010494 WO2005095403A2 (fr) 2004-03-30 2005-03-29 Composes macrocycliques inhibiteurs de replication virale

Country Status (16)

Country Link
EP (1) EP1749007A2 (fr)
JP (1) JP4950026B2 (fr)
AP (1) AP2006003763A0 (fr)
AR (1) AR050321A1 (fr)
AU (1) AU2005228894B9 (fr)
BR (1) BRPI0509467A (fr)
CA (1) CA2560897C (fr)
CU (1) CU23787B7 (fr)
EA (1) EA012389B1 (fr)
EC (1) ECSP066959A (fr)
GE (1) GEP20104926B (fr)
IL (1) IL177917A0 (fr)
MA (1) MA28548B1 (fr)
NO (1) NO20064933L (fr)
NZ (1) NZ549697A (fr)
WO (1) WO2005095403A2 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
US8957046B2 (en) 2007-03-30 2015-02-17 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US8993595B2 (en) 2009-04-08 2015-03-31 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US9045520B2 (en) 2008-12-23 2015-06-02 Gilead Pharmasset Llc Synthesis of purine nucleosides
US9163061B2 (en) 2007-12-21 2015-10-20 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
US9284307B2 (en) 2009-08-05 2016-03-15 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
US9498476B2 (en) 2008-06-04 2016-11-22 Albany Molecular Research, Inc. Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
US9499531B2 (en) 2004-07-15 2016-11-22 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US9549941B2 (en) 2011-11-29 2017-01-24 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2006096652A2 (fr) * 2005-03-08 2006-09-14 Boehringer Ingelheim International Gmbh Preparation de composes macrocycliques
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI387603B (zh) 2005-07-20 2013-03-01 Merck Sharp & Dohme Ｈｃｖ ｎｓ３蛋白酶抑制劑
KR101294467B1 (ko) 2005-07-25 2013-09-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 거대고리형 억제제
CN101273027B (zh) * 2005-07-29 2015-12-02 爱尔兰詹森科学公司 丙型肝炎病毒的大环抑制剂
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7772183B2 (en) * 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PL1966130T3 (pl) 2005-12-23 2014-05-30 Zealand Pharma As Zmodyfikowane związki mimetyczne lizyny
WO2008008776A2 (fr) 2006-07-11 2008-01-17 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
EA017448B1 (ru) 2006-07-13 2012-12-28 Ачиллион Фармасьютикалз, Инк. 4-амино-4-оксобутаноиловые пептиды как ингибиторы вирусной репликации
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) * 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
ES2357494T3 (es) * 2006-11-16 2011-04-27 Bristol-Myers Squibb Company Péptidos macrocíclicos como inhibidores de la hepatitis c.
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2468724B1 (fr) 2006-12-21 2015-11-18 Zealand Pharma A/S Synthèse de composés de pyrrolidine
US20100323953A1 (en) * 2007-01-08 2010-12-23 Phenomix Corporation Macrocyclic hepatitis c protease inhibitors
WO2008096002A1 (fr) * 2007-02-08 2008-08-14 Tibotec Pharmaceuticals Ltd. Phosphonates et amidophosphates macrocycliques inhibiteurs du vhc
EP2125113A2 (fr) 2007-02-26 2009-12-02 Achillion Pharmaceuticals, Inc. Peptides substitués par une amine tertiaire utiles comme inhibiteurs de la réplication du virus de l'hépatite c
CA2686138A1 (fr) 2007-05-03 2008-11-13 Intermune, Inc. Inhibiteurs macrocycliques innovants de la replication du virus de l'hepatite c
TW200918524A (en) * 2007-06-29 2009-05-01 Gilead Sciences Inc Antiviral compounds
AP2874A (en) * 2007-06-29 2014-03-31 Gilead Sciences Inc Antiviral compounds
AR068794A1 (es) 2007-06-29 2009-12-09 Gilead Sciences Inc Compuestos antivirales
SE531698C2 (sv) 2007-07-12 2009-07-07 Respiratorius Ab Nya bronkdilaterande a,b-omättade amider
US8309685B2 (en) 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
NZ586232A (en) 2007-12-21 2012-12-21 Avila Therapeutics Inc HCV protease inhibitors comprising a functionalised proline derivative
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
BRPI0821836A2 (pt) * 2007-12-24 2015-06-16 Tibotec Pharm Ltd Indóis macrocíclicos como inibidores do vírus da hepatite c
ES2388994T3 (es) * 2008-04-11 2012-10-22 F. Hoffmann-La Roche Ag Nuevos complejos de rutenio, como catalizadores para reacciones de metátesis
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2300491B1 (fr) 2008-05-29 2016-01-06 Bristol-Myers Squibb Company Inhibiteurs du virus de l hépatite c
CN102112442B (zh) * 2008-08-07 2014-12-10 弗·哈夫曼-拉罗切有限公司 制备大环的方法
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
NZ591030A (en) 2008-09-17 2012-10-26 Boehringer Ingelheim Int Combination of hcv ns3 protease inhibitor with interferon and ribavirin
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
NZ592668A (en) 2008-12-10 2013-12-20 Achillion Pharmaceuticals Inc New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
RU2536868C2 (ru) 2009-02-27 2014-12-27 Орто-Макнейл-Янссен Фармасьютикалз Инк Аморфная соль макроциклического ингибитора hcv
JP5739415B2 (ja) 2009-05-12 2015-06-24 ブリストル−マイヤーズ スクウィブ カンパニー （Ｓ）−７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンの結晶形態およびその使用
WO2010132437A1 (fr) 2009-05-12 2010-11-18 Albany Molecular Research, Inc. Aryle, hétéroaryle et tétrahydroisoquinolines à hétérocycle substitué et leur utilisation
EA020553B1 (ru) 2009-05-12 2014-12-30 Олбани Молекьюлар Рисерч, Инк. 7-([1,2,4]ТРИАЗОЛО[1,5-α]ПИРИДИН-6-ИЛ)-4-(3,4-ДИХЛОРФЕНИЛ)-1,2,3,4-ТЕТРАГИДРОИЗОХИНОЛИН, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ И ПСИХИЧЕСКИХ РАССТРОЙСТВ
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
AU2010270783B2 (en) 2009-07-07 2013-06-27 Boehringer Ingelheim International Gmbh Pharmaceutical composition for a hepatitis C viral protease inhibitor
US20110129444A1 (en) * 2009-09-28 2011-06-02 Intermune, Inc Novel macrocyclic inhibitors of hepatitis c virus replication
NZ598465A (en) 2009-10-30 2013-10-25 Boehringer Ingelheim Int Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
BR112012018529A2 (pt) 2010-01-25 2016-08-09 Enanta Pharm Inc inibidores do vírus de hepatite c, sua composição farmacêutica e seu uso, e método para inibição da replicação de um vírus contendo rna
EP3290428B1 (fr) 2010-03-31 2021-10-13 Gilead Pharmasset LLC Comprimé contenant cristallin (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
CA2794671C (fr) 2010-03-31 2018-05-01 Gilead Pharmasset Llc Synthese stereoselective d'agents actifs contenant du phosphore
EP2455068A1 (fr) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Composition pharmaceutique pour le traitement d'infections par VHC
BR112013012078A2 (pt) 2010-11-15 2019-09-24 Abbvie Inc inibidores de nampt e rock
CN103534256B (zh) 2010-12-30 2016-08-10 益安药业 大环丙型肝炎丝氨酸蛋白酶抑制剂
KR20140003521A (ko) 2010-12-30 2014-01-09 이난타 파마슈티칼스, 인코포레이티드 페난트리딘 매크로사이클릭 ｃ형 간염 세린 프로테아제 억제제
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
WO2013185284A1 (fr) 2012-06-12 2013-12-19 Abbott Laboratories Dérivés de pyridinone et de pyridazinone
JP6154474B2 (ja) 2012-10-19 2017-06-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914614B1 (fr) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
EP2964664B1 (fr) 2013-03-07 2017-01-11 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
CA2905433A1 (fr) 2013-03-14 2014-09-25 Achillion Pharmaceuticals, Inc. Processus innovants de production de sovaprevir
WO2014145600A1 (fr) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. Polymorphes de sel de sodium d'ach-0142684, composition les comprenant, et leur procédé de fabrication
WO2014145507A1 (fr) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. Procédé de fabrication d'un analogue cyclique de peptide de 4-amino-4-oxobutanoyle, inhibiteur de réplication virale et leurs intermédiaires
SG11201507467VA (en) 2013-03-15 2015-10-29 Achillion Pharmaceuticals Inc Sovaprevir polymorphs and methods of manufacture thereof
EP4005560A1 (fr) 2013-08-27 2022-06-01 Gilead Pharmasset LLC Formulation de combinaison de deux composés antiviraux
WO2015103490A1 (fr) 2014-01-03 2015-07-09 Abbvie, Inc. Formes galéniques antivirales solides
DK3618847T3 (da) 2017-05-05 2021-05-25 Boston Medical Ct Corp GAP-junction-modulatorer af intercellulær kommunikation og deres anvendelse til behandling af diabetisk øjensygdom

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000009543A2 (fr) * 1998-08-10 2000-02-24 Boehringer Ingelheim (Canada) Ltd. Tri-peptides inhibiteurs de l'hepatite c
WO2000009558A1 (fr) * 1998-08-10 2000-02-24 Boehringer Ingelheim (Canada) Ltd. Peptides inhibiteurs de l'hepatite c
WO2000059929A1 (fr) * 1999-04-06 2000-10-12 Boehringer Ingelheim (Canada) Ltd. Peptides macrocycliques actifs contre le virus de l'hepatite c
WO2003064456A1 (fr) * 2002-02-01 2003-08-07 Boehringer Ingelheim International Gmbh Tripeptides comprenant un hydroxyproline ether d'une quinoline substituee destines a inhiber ns3 (hepatite c)
WO2003064455A2 (fr) * 2002-01-30 2003-08-07 Boehringer Ingelheim (Canada) Ltd. Peptides macrocycliques actifs contre le virus de l'hepatite c
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US20030191067A1 (en) * 2002-02-01 2003-10-09 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60119968T2 (de) * 2000-11-20 2007-01-18 Bristol-Myers Squibb Co. Hepatitis c tripeptid inhibitoren
US6867185B2 (en) * 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
AU2003248535A1 (en) * 2002-05-20 2003-12-12 Bristol-Myers Squibb Company Heterocyclicsulfonamide hepatitis c virus inhibitors
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
CN102020697B (zh) * 2003-10-14 2014-10-29 F·霍夫曼-罗须公司 作为hcv复制抑制剂的巨环羧酸和酰基磺酰胺
DK1713823T3 (da) * 2004-01-30 2010-03-08 Medivir Ab HCV NS-3 serinproteaseinhibitorer

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000009543A2 (fr) * 1998-08-10 2000-02-24 Boehringer Ingelheim (Canada) Ltd. Tri-peptides inhibiteurs de l'hepatite c
WO2000009558A1 (fr) * 1998-08-10 2000-02-24 Boehringer Ingelheim (Canada) Ltd. Peptides inhibiteurs de l'hepatite c
WO2000059929A1 (fr) * 1999-04-06 2000-10-12 Boehringer Ingelheim (Canada) Ltd. Peptides macrocycliques actifs contre le virus de l'hepatite c
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
WO2003064455A2 (fr) * 2002-01-30 2003-08-07 Boehringer Ingelheim (Canada) Ltd. Peptides macrocycliques actifs contre le virus de l'hepatite c
WO2003064456A1 (fr) * 2002-02-01 2003-08-07 Boehringer Ingelheim International Gmbh Tripeptides comprenant un hydroxyproline ether d'une quinoline substituee destines a inhiber ns3 (hepatite c)
US20030191067A1 (en) * 2002-02-01 2003-10-09 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9499531B2 (en) 2004-07-15 2016-11-22 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US8957046B2 (en) 2007-03-30 2015-02-17 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US9585906B2 (en) 2007-03-30 2017-03-07 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US9163061B2 (en) 2007-12-21 2015-10-20 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
US9498476B2 (en) 2008-06-04 2016-11-22 Albany Molecular Research, Inc. Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
US9045520B2 (en) 2008-12-23 2015-06-02 Gilead Pharmasset Llc Synthesis of purine nucleosides
US8993595B2 (en) 2009-04-08 2015-03-31 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US9284307B2 (en) 2009-08-05 2016-03-15 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
US9549941B2 (en) 2011-11-29 2017-01-24 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus

Also Published As

Publication number Publication date
AU2005228894A1 (en) 2005-10-13
JP2007531749A (ja) 2007-11-08
NO20064933L (no) 2006-12-15
EA012389B1 (ru) 2009-10-30
NZ549697A (en) 2009-12-24
CA2560897C (fr) 2012-06-12
JP4950026B2 (ja) 2012-06-13
CU23787B7 (es) 2012-03-15
GEP20104926B (en) 2010-03-25
CU20090209A7 (es) 2011-04-26
WO2005095403A2 (fr) 2005-10-13
AP2006003763A0 (en) 2006-10-31
AR050321A1 (es) 2006-10-18
CA2560897A1 (fr) 2005-10-13
ECSP066959A (es) 2006-12-20
EA200601467A1 (ru) 2007-06-29
MA28548B1 (fr) 2007-04-03
IL177917A0 (en) 2006-12-31
AU2005228894B2 (en) 2011-08-25
EP1749007A2 (fr) 2007-02-07
BRPI0509467A (pt) 2007-09-11
AU2005228894B9 (en) 2011-10-13

Similar Documents

Publication Publication Date Title
WO2005095403A3 (fr) Composes macrocycliques inhibiteurs de replication virale
TNSN06308A1 (en) Macrocyclic compounds as inhibitors of viral replication
WO2007047146A3 (fr) Inhibiteurs de réplication virale
WO2007015824A3 (fr) Nouveaux inhibiteurs macrocycliques de la multiplication du virus de l’hépatite c
WO2008137779A3 (fr) Inhibiteurs macrocycliques innovants de la réplication du virus de l'hépatite c
WO2008005511A3 (fr) Nouveaux inhibiteurs de la réplication du virus de l'hépatite c
WO2009142842A3 (fr) Nouveaux inhibiteurs macrocycliques de la réplication du virus de l’hépatite c
WO2005037214A3 (fr) Acylsulfonamides et acides carboxyliques macrocycliques utilises en tant qu'inhibiteurs de la replication du virus de l'hepatite c
TN2009000481A1 (en) Novel peptide inhibitors of hepatitis c virus replication
WO2008100867A3 (fr) Nouveaux inhibiteurs de réplication du virus de l'hépatite c
WO2009134616A8 (fr) Nouveaux inhibiteurs de réplication du virus de l’hépatite c
WO2012087976A3 (fr) Nouveaux inhibiteurs de la réplication du virus de l'hépatite c
WO2008106058A3 (fr) Inhibiteurs de sérine protéases
MX2012003171A (es) Novedosos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
WO2005007681A3 (fr) Inhibiteurs de serines proteases, en particulier de la protease ns3-ns4a du vhc
WO2004112724A3 (fr) Compositions et procedes de traitement du vih
WO2006133194A3 (fr) Methodes permettant de traiter une infection virale a l'aide d'une solution medicamenteuse orale ou injectable
TNSN06103A1 (en) Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
TW200611905A (en) Macrocyclic compounds as inhibitors of viral replication
UA95455C2 (ru) Макроциклические ингибиторы репликации вируса гепатита с
WO2006085141A3 (fr) Compositions et methodes pour le traitement ou la prevention d'une infection provoquee par hepadnaviridae
UA84579C2 (ru) Макроциклические карбоновые кислоты и ацилсульфонамиды как ингибиторы репликации вируса гепатита с
TN2010000468A1 (en) Novel macrocyclic inhibitors of hepatitis c virus replication
CU23602A3 (es) Compuestos macrocíclicos como inhibidores de la replicación viral

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2005757750

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
B Later publication of amended claims

Effective date: 20051209

WWE Wipo information: entry into national phase

Ref document number: 549697

Country of ref document: NZ

Ref document number: 177917

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 200601467

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: DZP2005000454

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 2005228894

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 06093545

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2560897

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12006501882

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: AP/P/2006/003763

Country of ref document: AP

Ref document number: 200580010503.6

Country of ref document: CN

Ref document number: PA/a/2006/011268

Country of ref document: MX

Ref document number: 2007506466

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

ENP Entry into the national phase

Ref document number: 2005228894

Country of ref document: AU

Date of ref document: 20050329

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005228894

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006/08798

Country of ref document: ZA

Ref document number: 200608798

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 9674

Country of ref document: GE

Ref document number: 6333/DELNP/2006

Country of ref document: IN

Ref document number: 1200601778

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 1020067022763

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2005757750

Country of ref document: EP

Ref document number: 1020067022763

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0509467

Country of ref document: BR